Although Shalhout et al. examined cfDNA in MCC, the first application of bespoke ctDNA in MCC was to monitor treatment response in a patient whose disease had progressed on pembrolizumab, a programmed cell death-1 (PD-1) inhibitor [7]. The gene discussed is PDCD1; the disease is Merkel cell skin cancer.